Cabergoline and Hemianopia heteronymous - a phase IV clinical study of FDA data

Summary:

Hemianopia heteronymous is reported as a side effect among people who take Cabergoline (cabergoline), especially for people who are female, 20-29 old, also take Botox, and have Prolactin-producing pituitary tumor.

The phase IV clinical study analyzes which people have Hemianopia heteronymous when taking Cabergoline. It is created by eHealthMe based on reports of 5,946 people who have side effects when taking Cabergoline from the FDA, and is updated regularly.

What is Cabergoline?

Cabergoline has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 6,257 Cabergoline users. Check the latest studies of Cabergoline.

What is Hemianopia heteronymous?

Hemianopia heteronymous (loss of vision in either both nasal halves or both temporal halves of the visual field) is found to be associated with 16 drugs and 48 conditions by eHealthMe. Check the latest studies of Hemianopia heteronymous.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

5,946 people reported to have side effects when taking Cabergoline.
Among them, 12 people (0.2%) have Hemianopia heteronymous.

Could Cabergoline cause Hemianopia heteronymous?

Among these 12 people:

What is the gender of people who have Hemianopia heteronymous when taking Cabergoline? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Hemianopia heteronymous when taking Cabergoline? *

What are other drugs people take besides Cabergoline? *

Topamax: 1 person, 8.33%
Botox: 1 person, 8.33%

What are other side effects people have besides Hemianopia heteronymous? *

Empty Sella Syndrome (pituitary gland shrinks or becomes flattened): 8 people, 66.67%
Panic Disorder: 4 people, 33.33%
Balance Disorder: 4 people, 33.33%
Stress And Anxiety: 4 people, 33.33%
Dizziness: 4 people, 33.33%
Blindness: 3 people, 25.00%
Visual Pathway Disorder: 3 people, 25.00%
Headache (pain in head): 3 people, 25.00%
Neoplasm Progression (growth of tumour): 2 people, 16.67%
Glucocorticoid Deficiency (less glucocorticoids secretion from kidney): 1 person, 8.33%

What are the existing conditions these people have? *

Prolactin-Producing Pituitary Tumor: 8 people, 66.67%
Pituitary Tumor Benign: 2 people, 16.67%
Headache (pain in head): 1 person, 8.33%
Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Cabergoline and have Hemianopia heteronymous?

- Check whether Hemianopia heteronymous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabergoline:

Cabergoline (6,257 reports)

Browse all side effects of Cabergoline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hemianopia heteronymous:

Hemianopia heteronymous (16 drugs)

Browse all the conditions that are associated with Hemianopia heteronymous:

Hemianopia heteronymous (48 conditions)

Related publications that referenced our studies

Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .
Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Cabergoline) and Cabergoline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.